Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
Ashutosh Kumar, a materials science and engineering PhD student and MathWorks Fellow, applies his eclectic skills to studying the relationship between bacteria and cancer.